NervGen Pharma (NGEN) vs Cartesian Therapeutics (RNAC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cartesian Therapeutics (RNAC) has outperformed NervGen Pharma (NGEN) over the past year, losing 31.4% versus a loss of 44.1%. Over five years, NGEN leads with a -7.9% price change compared with -94.8% for RNAC. Cartesian Therapeutics is the larger company by market cap ($202.1 million vs $187.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NGEN | RNAC |
|---|---|---|
| Share price | $1.74 | $6.68 |
| Market cap | $187.09M | $202.11M |
| 1-day change | -0.57% | -1.04% |
| YTD return | -68.93% | -7.35% |
| 1-year return | -44.12% | -31.42% |
| 5-year return | -7.94% | -94.79% |
| EPS (TTM) | $-0.57 | $-5.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.30 | $11.00 |
| 52-week low | $1.58 | $5.60 |
| Distance from 52-week high | -72.38% | -39.27% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +474.71% | +404.04% |
| Average volume | 572.85K | 131.99K |
| Shares outstanding | 107.52M | 30.26M |
| Employees | 9 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RNAC has outperformed NGEN by 12.7 percentage points over the past year.
About NervGen Pharma
NGEN stock →NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About Cartesian Therapeutics
RNAC stock →Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
NGEN vs RNAC FAQ
Which is bigger, NervGen Pharma or Cartesian Therapeutics?
Cartesian Therapeutics (RNAC) is larger, with a market capitalization of $202.11M compared with $187.09M for NervGen Pharma (NGEN).
Which stock has performed better over the past year, NGEN or RNAC?
RNAC returned -31.42% over the past 12 months, compared with -44.12% for NGEN (price return, excluding dividends). Past performance does not predict future results.
Are NervGen Pharma and Cartesian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.